Pomalidomide improved immune profiles in myeloma (IMAGE)
Caption
Figure 1: Pomalidomide-mediated immune changes associated with PFS.
We have shown in three different immune cell-types, including T, B and NK cells, that the expression of a given immune marker in these cell-types is higher or lower than median level associated with better PFS in PVd treated patient population. We do not see this observation among Vd treated patients.
Credit
Copyright: © 2025 Seah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content